Journal
FUTURE ONCOLOGY
Volume 11, Issue 8, Pages 1153-1168Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.9
Keywords
continuous therapy; induction; multiple myeloma; newly diagnosed; oral administration; proteasome inhibition; refractory; relapsed
Categories
Funding
- Celgene
- Millennium Pharmaceuticals, Inc.
- Novartis
- Onyx
- Genzyme
- Cephalon
Ask authors/readers for more resources
Ixazomib is an investigational, reversible 20S proteasome inhibitor. It is the first oral proteasome inhibitor under clinical investigation in multiple myeloma (MM). Under physiological conditions, the stable citrate ester drug substance, ixazomib citrate (MLN9708), rapidly hydrolyzes to the biologically active boronic acid, ixazomib (MLN2238). Preclinical studies have demonstrated antitumor activity in MM cell lines and xenograft models. In Phase I/II clinical studies ixazomib has had generally manageable toxicities, with limited peripheral neuropathy observed to date. Preliminary data from these studies indicate ixazomib is active as a single agent in relapsed/refractory MM and as part of combination regimens in newly diagnosed patients. Phase III studies in combination with lenalidomide-dexamethasone are ongoing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available